Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 07 - 18 tags : Application save search
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
Published: 2022-07-18 (Crawled : 00:00) - biospace.com/
ACAD | $16.88 -1.11% 340K
|
Health Technology
|
| O: 0.65%
H: 2.31%
C: -2.41%
treatment fda drug application rett syndrome
Citrine Global Corp. (OTCQB: CTGL) Announced its Subsidiary Files Provisional Patent Application Targeting to Address Oral Cavity Side Effects Associated with the Use of Medicines, Treatments, Aging or an Unbalanced/Unhealthy Lifestyle
Published: 2022-07-18 (Crawled : 16:00) - globenewswire.com
CTGL | $0.0125 420
|
Manufacturing
| Email alert
Add to watchlist
patent global application
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2022-07-18 (Crawled : 14:20) - globenewswire.com
GNMSF | $290.38 220
|
Health Technology
|
| O: 0.15%
H: 4.93%
C: 2.47%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
GMAB | $28.805 1.68% 80K
|
Health Technology
|
| O: 0.82%
H: 1.15%
C: -1.16%
cd20 duobody treatment application authorization
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs
Published: 2022-07-18 (Crawled : 13:20) - biospace.com/
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 4.3%
H: 1.87%
C: 0.0%
acer-001 treatment drug application resubmission therapeutics
Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)
Published: 2022-07-18 (Crawled : 09:00) - biospace.com/
RLFTF | $1.43 3.8K
|
n/a
|
| O: 4.11%
H: 0.0%
C: -10.53%
acer-001 urea treatment fda drug collaboration application therapeutics
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
Published: 2022-07-18 (Crawled : 07:00) - prnewswire.com
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
treatment ema application migraine authorization
Gainers vs Losers
| 74% | 26% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
INSG | $2.98 23.14% 190K
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.